Switch theme
Sign up to access all valuation multiples
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo’s groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo’s headquarters in Uppsala, Sweden.
1995
110
LTM Revenue $59.8M
LTM EBITDA $3.4M
$111M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Orexo has a last 12-month revenue (LTM) of $59.8M and a last 12-month EBITDA of $3.4M.
In the most recent fiscal year, Orexo achieved revenue of $61.7M and an EBITDA of $6.1M.
Orexo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Orexo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $59.8M | XXX | $61.7M | XXX | XXX | XXX |
| Gross Profit | $52.1M | XXX | $54.2M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $3.4M | XXX | $6.1M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 10% | XXX | XXX | XXX |
| EBIT | -$8.1M | XXX | -$15.3M | XXX | XXX | XXX |
| EBIT Margin | -14% | XXX | -25% | XXX | XXX | XXX |
| Net Profit | -$13.5M | XXX | -$21.2M | XXX | XXX | XXX |
| Net Margin | -23% | XXX | -34% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $35.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Orexo's stock price is SEK 20 (or $2).
Orexo has current market cap of SEK 699M (or $73.1M), and EV of SEK 1.1B (or $111M).
See Orexo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $111M | $73.1M | XXX | XXX | XXX | XXX | $-0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Orexo has market cap of $73.1M and EV of $111M.
Orexo's trades at 1.8x EV/Revenue multiple, and 18.1x EV/EBITDA.
Equity research analysts estimate Orexo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Orexo has a P/E ratio of -5.4x.
See valuation multiples for Orexo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73.1M | XXX | $73.1M | XXX | XXX | XXX |
| EV (current) | $111M | XXX | $111M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 33.1x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | -13.7x | XXX | -7.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.4x | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | -18.1x | XXX | -28.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrexo's last 12 month revenue growth is -1%
Orexo's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.6M for the same period.
Orexo's rule of 40 is -5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Orexo's rule of X is 3% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Orexo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -5% | XXX | 9% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 3% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 113% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orexo acquired XXX companies to date.
Last acquisition by Orexo was XXXXXXXX, XXXXX XXXXX XXXXXX . Orexo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Orexo founded? | Orexo was founded in 1995. |
| Where is Orexo headquartered? | Orexo is headquartered in Sweden. |
| How many employees does Orexo have? | As of today, Orexo has 110 employees. |
| Who is the CEO of Orexo? | Orexo's CEO is Mr. Nikolaj Sorensen. |
| Is Orexo publicy listed? | Yes, Orexo is a public company listed on STO. |
| What is the stock symbol of Orexo? | Orexo trades under ORX ticker. |
| When did Orexo go public? | Orexo went public in 2005. |
| Who are competitors of Orexo? | Similar companies to Orexo include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Orexo? | Orexo's current market cap is $73.1M |
| What is the current revenue of Orexo? | Orexo's last 12 months revenue is $59.8M. |
| What is the current revenue growth of Orexo? | Orexo revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Orexo? | Current revenue multiple of Orexo is 1.9x. |
| Is Orexo profitable? | Yes, Orexo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Orexo? | Orexo's last 12 months EBITDA is $3.4M. |
| What is Orexo's EBITDA margin? | Orexo's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Orexo? | Current EBITDA multiple of Orexo is 33.1x. |
| What is the current FCF of Orexo? | Orexo's last 12 months FCF is -$6.2M. |
| What is Orexo's FCF margin? | Orexo's last 12 months FCF margin is -10%. |
| What is the current EV/FCF multiple of Orexo? | Current FCF multiple of Orexo is -18.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
